OBJECTIVE To explore the application value of pharmaceutical care interventions on chronic obstructive pulmonary disease(COPD) patients in the cough & wheeze physician-pharmacist joint clinic of pulmonary and critical care medicine(PCCM) based on the intelligent pharmaceutical care platform.

METHOD A total of 200 COPD patients who received treatment in the cough & wheeze physician-pharmacist joint clinic of PCCM of Affiliated Hospital of Nantong University between July 2021 and June 2022 were selected. These patients were randomly assigned to a control group(100 cases) and an experimental group(100 cases) according to random number method. The control group received routine medication guidance and health education. The experimental group, in addition to the control group, established a clinical pharmacists-led pharmaceutical care team based on the intelligent pharmaceutical care platform to standardize and individualize the management of COPD patients. The differences in treatment effect and quality of life were compared between the two groups.

RESULT The lung function index of forced expiratory volume in one second percent(FEV1%) and the forced expiratory volume in one second/forced vital capacity (FEV1/FVC%) were significantly higher in the experimental group than those in the control group(P<0.05), and the COPD Assessment Test(CAT) scores were significantly lower in the experimental group than those in the control group(P<0.05). The Eight-item Morisky Medication Adherence Scale(MMAS-8) scores in the experimental group were significantly higher than those in the control group(P<0.05). The rate of improper use of the inhalation device and the incidence of adverse drug reactions in the experimental group was significantly lower than those in the control group(P<0.05). The 6-minute walk test(6MWT) results in the experimental group were significantly higher than those in the control group(P<0.05). The St George’s Respiratory Questionnaire(SGRQ) weight scores in the experimental group were significantly lower than those in the control group(P<0.05). The satisfaction rate of patients in the experimental group with pharmaceutical care were significantly higher than that in the control group(P<0.05).

CONCLUSION The management of patients with COPD in the cough & wheeze physician-pharmacist joint clinic of PCCM based on the intelligent pharmaceutical care platform can significantly improve the patients’ lung function and treatment effect, increase the patients’ medication compliance, reduce the ADRs, and enhance the patients’ activity endurance and quality of life.